If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mgThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Following oral administration, lasmiditan is rapidly absorbed with a median Tmax of 1.8 hours.1
In patients with migraine, the absorption or PK of lasmiditan was not different during a migraine attack versus during the interictal period.1
The oral bioavailability over the clinical dose range of 50 mg to 200 mg is predicted to be 50% to 58%, based on the results from a population PK analysis.2
Lasmiditan may be taken with or without food as administration with meals was not associated with a clinically relevant effect on exposure to lasmiditan.1
Coadministration of lasmiditan with a high-fat meal
The human plasma protein binding of lasmiditan is
1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
AUC = area under the concentration
Cmax = maximum observed drug concentration
PK = pharmacokinetics
Tmax = time of maximum observed drug concentration
Date of Last Review: November 08, 2018
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST